Skip to main content

Myocardial Infarction, Acute

3
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
1 program
1
Cilostazol TabletsPhase 41 trial
Active Trials
NCT04407312Unknown60Est. Jul 2020
Cardior Pharmaceuticals
Cardior PharmaceuticalsGermany - Hanover
1 program
1
CDR132LPhase 2
Abbott
AbbottABBOTT PARK, IL
1 program
1
Stratified medicine - Microvascular dysfunction and eplerenone therapy, tabletsPhase 21 trial
Active Trials
NCT05198791Recruiting400Est. Jul 2026
MicroPort
MicroPortChina - Shanghai
1 program
Shortened DAPT followed by P2Y12 inhibitor monotherapyN/A1 trial
Active Trials
NCT04753749Completed2,248Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OtsukaCilostazol Tablets
AbbottStratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
MicroPortShortened DAPT followed by P2Y12 inhibitor monotherapy

Clinical Trials (3)

Total enrollment: 2,708 patients across 3 trials

NCT04407312OtsukaCilostazol Tablets

Cilostazol and Endothelial Progenitor Cell

Start: Jan 2016Est. completion: Jul 202060 patients
Phase 4Unknown
NCT05198791AbbottStratified medicine - Microvascular dysfunction and eplerenone therapy, tablets

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

Start: Feb 2022Est. completion: Jul 2026400 patients
Phase 2Recruiting
NCT04753749MicroPortShortened DAPT followed by P2Y12 inhibitor monotherapy

Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

Start: Mar 2021Est. completion: May 20252,248 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,708 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.